Yin-Ling Chen1, Yong-Chao Qiao2, Yan-Hong Pan1, Yan Xu2, Yong-Cheng Huang3, Yin-Hui Wang1, Li-Jun Geng1, Hai-Lu Zhao4, Xiao-Xi Zhang5. 1. Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin 541004, China; Department of Immunology, Faculty of Basic Medical Science, Guilin Medical University, Guilin 541004, China. 2. Department of Immunology, School of Basic Medicine, Central South University, Changsha, Hunan 410078, China. 3. Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin 541004, China. 4. Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin 541004, China; Department of Immunology, School of Basic Medicine, Central South University, Changsha, Hunan 410078, China; Department of Immunology, Faculty of Basic Medical Science, Guilin Medical University, Guilin 541004, China. 5. Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin 541004, China; Department of Immunology, Faculty of Basic Medical Science, Guilin Medical University, Guilin 541004, China. Electronic address: mike-527@163.com.
Abstract
OBJECTIVE: This report aimed to explore the association between the change of circulating interleukin-6 (IL-6) in patients and the development of type 1 diabetes mellitus (T1DM). METHODS: Four databases (PubMed, CNKI, WanFang and Civip) were used to search and list all clinical case-control studies about serum IL-6 level in T1DM patients between Jan 1, 2000 and Aug 31, 2016. RESULTS: A total of 20 case-control studies with 1238 T1DM patients and 742 healthy controls were included in this study. Compared to healthy controls, the serum content of IL-6 in patients with T1DM was significantly greater (overall: SMD, 1.49; 95% CI, 1.04 to 1.93; p<0.001), and notably increased in all subgroup with different age, ethnic and disease duration (all p<0.001). Furthermore, the analysis in subgroup exhibited that serum levels of IL-6 in the age greater than 20-year old (SMD, 1.64; 95% CI, 0.57-2.71; p<0.001), the diseased duration among 0-10years (SMD, 2.43; 95% CI, 1.42-3.44; p<0.001) and the sorted American group (SMD, 1.68; 95% CI, 0.85-2.51; p<0.001) were higher than those in control groups. CONCLUSIONS: Patients with T1DM were found to be linked to elevated level of serum IL-6, which the age, ethnic and disease durations in T1DM patients had no effect on the serum IL-6 levels for promoting diabetes mellitus.
OBJECTIVE: This report aimed to explore the association between the change of circulating interleukin-6 (IL-6) in patients and the development of type 1 diabetes mellitus (T1DM). METHODS: Four databases (PubMed, CNKI, WanFang and Civip) were used to search and list all clinical case-control studies about serum IL-6 level in T1DM patients between Jan 1, 2000 and Aug 31, 2016. RESULTS: A total of 20 case-control studies with 1238 T1DM patients and 742 healthy controls were included in this study. Compared to healthy controls, the serum content of IL-6 in patients with T1DM was significantly greater (overall: SMD, 1.49; 95% CI, 1.04 to 1.93; p<0.001), and notably increased in all subgroup with different age, ethnic and disease duration (all p<0.001). Furthermore, the analysis in subgroup exhibited that serum levels of IL-6 in the age greater than 20-year old (SMD, 1.64; 95% CI, 0.57-2.71; p<0.001), the diseased duration among 0-10years (SMD, 2.43; 95% CI, 1.42-3.44; p<0.001) and the sorted American group (SMD, 1.68; 95% CI, 0.85-2.51; p<0.001) were higher than those in control groups. CONCLUSIONS:Patients with T1DM were found to be linked to elevated level of serum IL-6, which the age, ethnic and disease durations in T1DM patients had no effect on the serum IL-6 levels for promoting diabetes mellitus.
Authors: Filip Roudnicky; Yanjun Lan; Max Friesen; Gregor Dernick; Jitao David Zhang; Andreas Staempfli; Natalie Bordag; Antje Wagner-Golbs; Klaus Christensen; Martin Ebeling; Martin Graf; Mark Burcin; Claas Aiko Meyer; Chad A Cowan; Christoph Patsch Journal: Int J Mol Sci Date: 2019-12-09 Impact factor: 5.923
Authors: William H Lagarde; Kecia L Courtney; Barry Reiner; Kimberly Steinmann; Eva Tsalikian; Steven M Willi Journal: Pediatr Diabetes Date: 2020-12-13 Impact factor: 4.866